# Rifamycin SV-MMX® 600 mg Tablets Administered Three or Two Times Daily to Patients With IBS-D

> **NCT03099785** · PHASE2 · COMPLETED · sponsor: **Cosmo Technologies Ltd** · enrollment: 279 (actual)

## Conditions studied

- Diarrhea-predominant Irritable Bowel Syndrome

## Interventions

- **DRUG:** Rifamycin SV 600mg t.i.d.
- **DRUG:** Rifamycin SV b.i.d. + Placebo
- **DRUG:** Placebo t.i.d.

## Key facts

- **NCT ID:** NCT03099785
- **Lead sponsor:** Cosmo Technologies Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-18
- **Primary completion:** 2020-09-11
- **Final completion:** 2020-12-14
- **Target enrollment:** 279 (ACTUAL)
- **Last updated:** 2021-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03099785

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03099785, "Rifamycin SV-MMX® 600 mg Tablets Administered Three or Two Times Daily to Patients With IBS-D". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03099785. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*